MCID: PDT040
MIFTS: 29

Pediatric Hypertension

Categories: Rare diseases

Aliases & Classifications for Pediatric Hypertension

MalaCards integrated aliases for Pediatric Hypertension:

Name: Pediatric Hypertension 54

Classifications:



Summaries for Pediatric Hypertension

MalaCards based summary : Pediatric Hypertension is related to hypertension, essential and aortic coarctation. An important gene associated with Pediatric Hypertension is AGT (Angiotensinogen), and among its related pathways/superpathways are Peptide hormone metabolism and Renin secretion. The drugs Ramipril and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and testes.

Related Diseases for Pediatric Hypertension

Graphical network of the top 20 diseases related to Pediatric Hypertension:



Diseases related to Pediatric Hypertension

Symptoms & Phenotypes for Pediatric Hypertension

Drugs & Therapeutics for Pediatric Hypertension

Drugs for Pediatric Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
3
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
4
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Amlodipine Approved Phase 4 88150-42-9 2162
7
Calcium Approved, Nutraceutical Phase 4,Phase 2 7440-70-2 271
8
protease inhibitors Phase 4,Phase 3
9 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3
10 HIV Protease Inhibitors Phase 4,Phase 3
11 Antihypertensive Agents Phase 4,Phase 3,Phase 2
12 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
13 Giapreza Phase 4,Phase 3,Phase 2
14 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
15 Angiotensinogen Phase 4,Phase 3,Phase 2
16 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
17 Calcium, Dietary Phase 4,Phase 2
18 Cardiotonic Agents Phase 4
19 Natriuretic Agents Phase 4
20 Vasodilator Agents Phase 4,Phase 2
21 Sodium Chloride Symporter Inhibitors Phase 4
22 Hormones Phase 4,Phase 2
23 diuretics Phase 4
24 calcium channel blockers Phase 4,Phase 2
25 Protective Agents Phase 4
26
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
27
Azilsartan medoxomil Approved, Investigational Phase 3 863031-21-4
28
Candesartan cilexetil Approved Phase 3 145040-37-5 2540
29
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
30
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
31
Enalaprilat Approved Phase 3 76420-72-9 6917719
32
Candesartan Experimental Phase 3 139481-59-7 2541
33 Pharmaceutical Solutions Phase 3
34 Neurotransmitter Agents Phase 3
35 Autonomic Agents Phase 3
36 Adrenergic Agents Phase 3
37 Adrenergic Antagonists Phase 3
38 Adrenergic beta-Antagonists Phase 3
39 Adrenergic beta-1 Receptor Antagonists Phase 3
40 Sympatholytics Phase 3
41 Peripheral Nervous System Agents Phase 3
42
Sulfamethazine Approved, Investigational, Vet_approved Not Applicable 57-68-1 5327

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 Treatment of Pediatric Hypertension With Altace Trial Completed NCT00044265 Phase 4 ramipril
2 N-of-1 Trials In Children With Hypertension Recruiting NCT03461003 Phase 4 Amlodipine;Lisinopril;Hydrochlorothiazide;Losartan
3 A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension Completed NCT00171028 Phase 3 valsartan
4 A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension Completed NCT02451150 Phase 3 Azilsartan
5 Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age Completed NCT00244634 Phase 3 candsartan cilexetil
6 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD Completed NCT01617681 Phase 3 VAL489;VAL489 matching placebo
7 Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects Completed NCT00255528 Phase 3 metoprolol succinate
8 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed NCT00255502 Phase 3 metoprolol succinate
9 Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age Completed NCT00244621 Phase 3 candesartan cilexetil (Atacand);candesartan cilexetil (Atacand);candesartan cilexetil (Atacand)
10 Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age Completed NCT00244595 Phase 3 candsartan cilexetil
11 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01150357 Phase 3 Aliskiren (6.25/12.5/25 mg);Aliskiren (37.5/75/150 mg);Aliskiren (150/300/600 mg)
12 A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age Completed NCT00171041 Phase 3 valsartan
13 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01151410 Phase 3 Aliskiren;Enalapril
14 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension Active, not recruiting NCT02791438 Phase 3 TAK-536 2.5 mg;TAK-536 5 mg
15 An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension Active, not recruiting NCT02235909 Phase 3 Azilsartan Medoxomil;Losartan;Placebo for Azilsartan Medoxomil;Placebo for Losartan
16 Preventing Sickle Cell Kidney Disease Recruiting NCT02373241 Phase 2 Losartan;Losartan
17 A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension Withdrawn NCT00528827 Phase 2 Cardene® I.V.
18 Improving Outcomes for Hypertensive Children Completed NCT01485783
19 Ewha Birth and Growth Study (Birth Cohort) Active, not recruiting NCT03351595
20 Pediatric Hypertension Registry (PHREG) Enrolling by invitation NCT03305562
21 Boosting Primary Care Awareness and Treatment of Childhood Hypertension Enrolling by invitation NCT03783650 Not Applicable

Search NIH Clinical Center for Pediatric Hypertension

Genetic Tests for Pediatric Hypertension

Anatomical Context for Pediatric Hypertension

MalaCards organs/tissues related to Pediatric Hypertension:

42
Kidney, Heart, Testes

Publications for Pediatric Hypertension

Articles related to Pediatric Hypertension:

(show top 50) (show all 135)
# Title Authors Year
1
Pediatric Hypertension: Diagnosis, Evaluation, and Treatment. ( 30454750 )
2019
2
Systematic reviews: a small fraction of the evidence used to generate the 2017 clinical pediatric hypertension clinical practice guideline. ( 30640876 )
2019
3
Pediatric hypertension and hypertensive emergencies: recognition and management in the emergency department. ( 30794368 )
2019
4
Blood Pressure Trajectories from Childhood to Adolescence in Pediatric Hypertension. ( 30808073 )
2019
5
Points & Pearls: Pediatric hypertension and hypertensive emergencies: recognition and management in the emergency department ( 30821950 )
2019
6
Coarctation of the Aorta in Adolescence: Significance of Detailed Cardiac Examination in Pediatric Hypertension. ( 30973498 )
2019
7
Impact of updated pediatric hypertension guidelines on progression from elevated blood pressure to hypertension in a community-based primary care population. ( 30980615 )
2019
8
2017 Pediatric Hypertension Guidelines Improve Prediction of Adult Cardiovascular Outcomes. ( 31006329 )
2019
9
Research Gaps in Primary Pediatric Hypertension. ( 31023830 )
2019
10
Pediatric hypertension: Cardiovascular prevention must begin early in life. ( 31029492 )
2019
11
Updates to pediatric hypertension guidelines: influence on classification of high blood pressure in children and adolescents. ( 30044314 )
2019
12
Target Organ Abnormalities in Pediatric Hypertension. ( 30122368 )
2018
13
Pediatric hypertension: diagnostic patterns derived from electronic health records. ( 30130249 )
2018
14
Pediatric Hypertension. ( 30543379 )
2018
15
Importance of ambulatory blood pressure monitoring in the diagnosis and prognosis of pediatric hypertension. ( 29871785 )
2018
16
Cardiac and Vascular Target Organ Damage in Pediatric Hypertension. ( 29881718 )
2018
17
Clinical Implications of the Revised AAP Pediatric Hypertension Guidelines. ( 29976572 )
2018
18
Surveillance of Pediatric Hypertension Using Smartphone Technology. ( 30005962 )
2018
19
Home blood pressure monitoring in pediatric hypertension: the US perspective and a plan for action. ( 30054592 )
2018
20
Editorial: Pediatric Hypertension: Update. ( 30109219 )
2018
21
Definition of pediatric hypertension: are blood pressure measurements on three separate occasions necessary? ( 28077857 )
2017
22
Can Pediatric Hypertension Criteria Be Simplified? A Prediction Analysis of Subclinical Cardiovascular Outcomes From the Bogalusa Heart Study. ( 28223474 )
2017
23
Hypertension Canada's 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. ( 28449829 )
2017
24
Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 28553631 )
2017
25
Pediatric Hypertension: Provider Perspectives. ( 28620629 )
2017
26
Primary Pediatric Hypertension: Current Understanding and Emerging Concepts. ( 28780627 )
2017
27
Adverse Outcomes in Pediatric Hypertension. ( 29084875 )
2017
28
Changes in the 2017 Pediatric Hypertension Clinical Guidelines. ( 29087430 )
2017
29
Commentary: Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 29164085 )
2017
30
Abnormalities of vascular structure and function in pediatric hypertension. ( 26275663 )
2016
31
Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity. ( 26389821 )
2016
32
Pharmacologic Management of Pediatric Hypertension. ( 26597490 )
2016
33
Re: Pediatric Hypertension and Cardiac Hypertrophy. ( 26739585 )
2016
34
Assessment of Left Ventricular Mass and Hypertrophy by Cardiovascular Magnetic Resonance Imaging in Pediatric Hypertension. ( 26988578 )
2016
35
Vascular Aging: Lessons From Pediatric Hypertension. ( 27040097 )
2016
36
Pharmacologic Treatment of Pediatric Hypertension. ( 27048353 )
2016
37
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, and Assessment of Risk of Pediatric Hypertension. ( 27118292 )
2016
38
In-Clinic Blood Pressure Prediction of Normal Ambulatory Blood Pressure Monitoring in Pediatric Hypertension Referrals. ( 27205889 )
2016
39
Pediatric Hypertension: Are Pediatricians Following Guidelines? ( 27659546 )
2016
40
Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. ( 27940711 )
2016
41
Executive function and cerebrovascular reactivity in pediatric hypertension. ( 23877480 )
2015
42
Pediatric Hypertension Specialists' Perspectives About Adolescent Hypertension Management: Implications for Primary Care Providers. ( 25398627 )
2015
43
Diagnosis of primary versus secondary pediatric hypertension. ( 25594296 )
2015
44
Pediatric hypertension: a growing problem. ( 25634711 )
2015
45
Recent clinical and translational advances in pediatric hypertension. ( 25712720 )
2015
46
The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension. ( 25794952 )
2015
47
Pediatric hypertension: a pharmacological review. ( 25898872 )
2015
48
Pediatric hypertension in the Eastern Province of Saudi Arabia. ( 25987114 )
2015
49
Cardiovascular target organ damage could have been detected in sustained pediatric hypertension. ( 26024395 )
2015
50
Is Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension? ( 26140344 )
2015

Variations for Pediatric Hypertension

Expression for Pediatric Hypertension

Search GEO for disease gene expression data for Pediatric Hypertension.

Pathways for Pediatric Hypertension

Pathways related to Pediatric Hypertension according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.22 ACE AGT
2 10.46 ACE AGT

GO Terms for Pediatric Hypertension

Biological processes related to Pediatric Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.46 ACE AGT
2 positive regulation of protein binding GO:0032092 9.43 ACE ADD1
3 regulation of blood pressure GO:0008217 9.4 ACE AGT
4 positive regulation of protein tyrosine kinase activity GO:0061098 9.37 ACE AGT
5 blood vessel remodeling GO:0001974 9.32 ACE AGT
6 regulation of vasoconstriction GO:0019229 9.26 ACE AGT
7 positive regulation of blood pressure GO:0045777 9.16 ACE AGT
8 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE AGT
9 regulation of renal output by angiotensin GO:0002019 8.62 ACE AGT

Sources for Pediatric Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....